Liquidia Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
8analysts covering
FY EPS (est.)
$3.23next fiscal year
Monitoring Framework
Key Performance Indicators
YUTREPIA Net Product Sales Quarterly129.9M
Unique Patient Prescriptions Monthly4.5K
Watch Items
- Patent Litigation with United TherapeuticsTrigger: Supreme Court or Federal Circuit rulings on the '327 patentAction: Re-evaluate market exclusivity duration and adjust long-term revenue projections
- L606 Phase III Registrational Study ProgressTrigger: Completion of patient enrollment or top-line data readoutAction: Update pipeline valuation and launch timeline assumptions for broader indications
Research as of 19 Jun 2026